Efficacy and safety of rituximab for membranous nephropathy in adults: a meta-analysis of RCT [0.03%]
利妥昔单抗治疗成人膜性肾病的疗效和安全性：随机对照试验的荟萃分析
Baike Mao,Jiahui Han,Jia Wang et al.
Baike Mao et al.
Background: Membranous nephropathy (MGN) represents a significant challenge in nephrology, with Rituximab emerging as a potential therapeutic intervention. ...
Real-world challenges associated with the use of four common systemic glucocorticoids in a United States IgAN cohort [0.03%]
美国IgA肾病队列中4种常见全身性糖皮质激素使用的实际挑战
Giancarlo Pesce,Mit Patel,Gaelle Gusto et al.
Giancarlo Pesce et al.
Objectives: To understand the difference in adverse events (AEs), healthcare resource utilization (HCRU), and kidney failure rates in immunoglobulin A nephropathy (IgAN) patients who initiated systemic glucocorticoid (SGC...
Nicoletta Mancianti,Marta Calatroni,Giacomo Deferrari et al.
Nicoletta Mancianti et al.
Xuefei Tian,Leopoldo Ardiles,Clay A Block
Xuefei Tian
Rogerio Passos,Bruno Zawadzki,Etienne Macedo et al.
Rogerio Passos et al.
Case Report: a novel variant in WT1 leads to focal segmental glomerulosclerosis and uterovaginal anomalies through exon skipping [0.03%]
案例报告：一种新的WT1变异体通过外显子跳过导致局灶节段性肾小球硬化和子宫阴道畸形
Jonathan Marquez,Lauren O&#x;Sullivan,Audrey E Squire et al.
Jonathan Marquez et al.
Background: Podocytopathies are a varied set of renal diseases in which podocytes are unable to perform their typical filtration function within the glomerulus. This typically leads to edema, proteinuria, and hypoalbumine...
Efficacy of febuxostat on hyperuricemia and estimated glomerular filtration rate in patients with non-dialysis stage 3/4 chronic kidney disease and assessment of cardiac function: a 12-month interventional study [0.03%]
非布司他治疗3/4期非透析慢性肾脏病患者高尿酸血症及肾小球滤过率疗效的12个月前瞻性队列研究及心脏功能评估
Yousuf Abdulkarim Waheed,Fan Yang,Jie Liu et al.
Yousuf Abdulkarim Waheed et al.
Objectives: Febuxostat, an oral medication for treating hyperuricemia (HUA), is a non-purine xanthine oxidase inhibitor that regulates serum uric acid (SUA) metabolism in patients with chronic kidney disease (CKD). Howeve...
Short-term outcome of levamisole in frequently relapsing nephrotic syndrome: a single-center prospective cohort study [0.03%]
利什曼素治疗频复发性肾病综合征的短期疗效分析：单中心前瞻性队列研究
Sabeeta Khatri,Irshad Ali Bajeer,Aasia Zubair et al.
Sabeeta Khatri et al.
Introduction: This study aims to describe the outcome of levamisole (LEVA) treatment in children with frequently relapsing nephrotic syndrome (FRNS). Meth...
Editorial: Novel diagnostic and prognostic methods in acute kidney injury among patients in intensive care unit [0.03%]
急性肾损伤的新型诊断和预后方法：重症监护病房患者的诊治举措
Marco Fiorentino
Marco Fiorentino
The kidney injury biomarker profile of patients with lupus nephritis remains unchanged with the second-generation calcineurin inhibitor voclosporin [0.03%]
使用第二代钙调磷酸酶抑制剂Voclosporin对狼疮肾炎患者的肾脏损伤生物标志物谱没有影响
Biff F Palmer,James A Tumlin,Jai Radhakrishnan et al.
Biff F Palmer et al.
Objectives: Kidney injury in patients with lupus nephritis (LN) results in pro-fibrotic biomarker expression, a manifestation also observed with calcineurin inhibitor (CNI) therapy. The second-generation CNI, voclosporin,...